Streetbeat News

Revenues

SPY

The NAHB Housing Market Index for February reported a value of 48, surpassing the estimated 46 and the previous month's 44. This indicates a positive trend in the housing market sentiment.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 3:01 pm

INTA

Intapp (NASDAQ:INTA) has seen a shift in analyst ratings over the last three months, with a recent increase in the average 12-month price target to $49.5 from $45.00, indicating a bullish sentiment. Analysts from Barclays, Stifel, Truist Securities, and Citigroup have raised their price targets, reflecting positive market dynamics and company performance. Intapp, a provider of cloud-based solutions for professional and financial services, has shown a revenue growth of 22.72% as of December 31, 2023, but faces challenges with below-average net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 15, 2024 | 3:01 pm

ACGL

Arch Capital Group (NASDAQ:ACGL) has received mixed analyst ratings over the past three months, with a recent shift towards a neutral stance. The average 12-month price target is $90.6, slightly down from $90.67. Analysts from JP Morgan, Citigroup, UBS, and Evercore ISI Group have adjusted their ratings and price targets, reflecting their views on the company's performance and market conditions. Arch Capital operates in insurance, reinsurance, and mortgage sectors, showing substantial market capitalization and revenue growth but lagging in ROE and ROA compared to industry averages.

Portfolio Pulse from Benzinga Insights

February 15, 2024 | 3:01 pm

SRPT

In the past three months, 13 analysts have provided diverse ratings for Sarepta Therapeutics (NASDAQ:SRPT), ranging from bullish to bearish. The average 12-month price target for SRPT has increased by 24.79% to $157.23. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting their views on the company's performance and market conditions. Sarepta Therapeutics, a biotech firm focusing on rare diseases, shows a revenue growth of 44.1% but faces challenges in profitability and financial risk due to a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 15, 2024 | 3:00 pm

IVDA

Iveda (NASDAQ:IVDA) has expanded its smart city technology footprint in Egypt by opening a new office in Cairo and a strategic demonstration showcase within the Arab Organization for Industrialization (AOI) government facility. This move, following a partnership with AOI six months ago, aims to display Iveda's 5G, AI, and sustainable technology innovations, including the Utilus Smart Pole. The collaboration supports Egypt's plan to introduce 38 new smart cities by 2050, leveraging Iveda's IoT and AI expertise. Egypt's AI market is expected to grow significantly, reaching $601.8 million by 2030. Major General Ashraf Hassan, a recent addition to Iveda's Advisory Board, will play a key role in promoting Iveda's technologies in the region.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 2:06 pm

DTSS

DataSea has entered into a $30M service agreement with Chongda for the provision of 5G Multimodal Communication Delivery Services. The agreement spans 12 months starting February 3, 2024. This deal underscores DataSea's capabilities in the 5G technology space and its potential for growth.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 2:06 pm

LLY

NVO

Novo Nordisk's weight-loss drug Wegovy is gaining popularity among U.S. adolescents battling obesity, with a significant increase in prescriptions from 25 in 2022 to 1,268 in the first ten months of 2023. Despite the surge, the overall numbers remain modest compared to the nearly 20% of U.S. children affected by obesity. Novo Nordisk and Eli Lilly are expanding their weight-loss drug trials to younger age groups, raising concerns among medical experts about the potential effects on child development. Novo Nordisk's shares are slightly down in premarket trading.

Portfolio Pulse from Vandana Singh

February 15, 2024 | 2:05 pm

EWJ

EWU

SPY

Brainard comments on global economic growth, noting improvements in some emerging markets. The U.S. recovery is highlighted as taking a different path compared to the UK and Japan, with the U.S. defying recession predictions.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 2:03 pm

BTCUSD

CSCO

ETHUSD

LMT

PFE

Cryptocurrencies surge with Bitcoin's market cap surpassing $1 trillion, potentially hitting $60K. US markets see mixed movements, with Cisco issuing a weak outlook. Global politics and economy updates include sanctions on Russia and BRICS nations challenging G7 dominance. Tech highlights include Uber's price target boost and Apple's AI chip advancements. Electric Vehicle sector notes Tesla's market strategies and challenges. New York City sues major social platforms over mental health concerns. Pfizer settles a lawsuit, and Lockheed Martin faces budget cuts on F-35 orders.

Portfolio Pulse from Akanksha Bakshi

February 15, 2024 | 2:02 pm

MLM

Martin Marietta Materials (NYSE:MLM) received mixed analyst ratings over the past three months, with an updated average 12-month price target of $589.5, marking a 13.0% increase from the previous target. The company's financial performance shows strong revenue growth and net margin but faces challenges in ROE, ROA, and debt management. Analysts from Truist Securities, Raymond James, Morgan Stanley, and Stifel have adjusted their ratings and price targets, reflecting a positive outlook on MLM's market position and performance.

Portfolio Pulse from Benzinga Insights

February 15, 2024 | 2:01 pm